Mode
Text Size
Log in / Sign up
N/A N=105

Piloting a Virtual Navigation (VN) System for Bronchoscopic Lung Nodule Sampling

Lung Cancer

Enrolled (actual)
105
Serious AEs
0.0%
Results posted
May 2026
Primary outcome: Primary: Safety Measurement — 0; 0; 0; 0 Adverse events

Study Design & Population

Study type
Observational
Phase
N/A
Interventions
Virtual Navigation System (Diagnostic_test)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Penn State University
Primary completion
Nov 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Safety Measurement
0; 0; 0; 0
PRIMARY
Functionality Measurement
0; 0
PRIMARY
Diagnostic Biopsy Yield
35; 45
PRIMARY
Radial Endobronchial Ultrasound (EBUS) Probe Passes
7.7; 1
PRIMARY
Comparison of the Number of Lymph Nodes and Nodal Stations Visited
2.67; 5.69
SECONDARY
Tumor Pathology
6; 2; 20; 8; 7; 37
SECONDARY
Procedure Complications
1; 0; 0; 0
SECONDARY
Distance From Final Selected Site to the Pre-planned Optimal Site
5.88
SECONDARY
Procedure Time
3540; 6120; 3060; 4140; 56.7; 144

Summary

The overall goal is to evaluate the role of a Virtual Navigation (VN) system (the Virtual Navigator) in the bronchoscopic evaluation and tissue sampling of lung cancer and other chest lesions at the Penn State Hershey Medical Center (HMC). The Virtual Navigator is a software package that runs on a mobile Windows-based computer. The computer takes in up to four clinical image/video sources, ordered by the clinician for clinical purposes: 1) 3D CT (computed tomography) imaging scan; 2) 3D PET (positron emission tomography) imaging scan (optional); 3) Bronchoscopic video of the airway tree interior; 4) Ultrasound video of scanned anatomy outside the airways, as provided by an endobronchial ultrasound (EBUS) probe (optional). During a live guided procedure, the Virtual Navigator presents images that assist with navigating the bronchoscope to predesignated chest lesions. Lung cancer patients that present a suspicious peripheral tumor on their chest CT scan are often prescribed to undergo a diagnosis-and-staging bronchoscopy, whereby the bronchoscopist examines both the suspect tumor and any identified central-chest lymph nodes. For the clinical study, we consider bronchoscopy performance for two cohorts: 1) a cohort of consented patients who undergo image-guided bronchoscopy via the Virtual Navigator; and 2) a historical controls cohort consisting of patients who underwent bronchoscopy recently at our medical center (state-of-the-art bronchoscopy practice). The study's general hypothesis is that an image-guided bronchoscopy system (the Virtual Navigator) that integrates 3D imaging, bronchoscopy, and EBUS images enables more complete evaluation and sampling of chest lesions than current state-of-the-art clinical techniques. More specifically, for peripheral-tumor diagnosis, the sub-hypothesis is that the VN system increases diagnostic biopsy yield as compared to state-of-the-art bronchoscopy practice; for central-chest nodal staging, the sub-hypothesis is that the VN system enables the sampling of more lymph nodes than state-of-the-art bronchoscopy practice.

Eligibility Criteria

Inclusion Criteria

  • patients from age 18 and over
  • a planned clinical bronchoscopy to evaluate abnormal lung parenchyma and/or central chest lymph nodes
  • a clinical CT scan performed at Hershey Medical Center that meets technical specifications and is available on the Radiology research server
  • (Optional, use if available) CT/PET images that meet technical specifications and are available on the Hershey Medical Center clinical image storage system

Exclusion Criteria

  • inability to give consent
  • the CT scan does not meet technical specifications
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05599321). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search